8-K - Arrowhead Pharmaceuticals, Inc. | StockGist

Current Report Details

Event Type

Material Agreement

Financing

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. Indenture and Notes On January 12, 2026, Arrowhead Pharmaceuticals, Inc. (the “Company”) issued $700,000,000 aggrega

Material Agreement

$75.0M$75.0M$1.0K$87.07J.P. Morgan Securities LLC

Source Document

2.03

. Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 4.1 Indenture, dated as of January 12, 2026, between Arrowhead Pharmaceuti

Financing

Exhibits (5)

10.1

EX-10.1

4.1

EX-4.1

4.2

EX-4.2

5.1

EX-5.1

8-K